Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Melphalan 16Dexamethasone 15Bortezomib 11Peripheral Blood Stem Cell Transplantation 9Lenalidomide 9fludarabine phosphate 8Calcium Dobesilate 7pomalidomide 5fludarabine 5Busulfan 5carfilzomib 4Radiotherapy 4Prednisone 4Cyclophosphamide 4liposomal doxorubicin 3daratumumab 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Filgrastim 3Cyclosporine 3Arsenic Trioxide 3Alemtuzumab 3samarium Sm-153 lexidronam 2holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 2Whole-Body Irradiation 2Surveys and Questionnaires 2Pneumococcal Vaccines 2Granulocyte Colony-Stimulating Factor 2Bendamustine Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Plasma Cell × alethine × Clear all
NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡